Home » Stocks » GNCA

Genocea Biosciences, Inc. (GNCA)

Stock Price: $3.24 USD -0.02 (-0.61%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $3.25 +0.01 (0.31%) Jan 21, 5:56 PM
Market Cap 167.30M
Revenue (ttm) 1.36M
Net Income (ttm) -38.09M
Shares Out 55.49M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $3.24
Previous Close $3.26
Change ($) -0.02
Change (%) -0.61%
Day's Open 3.33
Day's Range 3.06 - 3.40
Day's Volume 819,058
52-Week Range 1.26 - 5.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announce...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announce...

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies

GlobeNewsWire - 2 months ago

Call scheduled for November 9th at 8:30 a.m. EST Call scheduled for November 9th at 8:30 a.m. EST

Seeking Alpha - 2 months ago

Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its t...

Zacks Investment Research - 3 months ago

Is (GNCA) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 3 months ago

Will showcase clinical and immune response s from the ongoing GEN-009 Phase 1/2a trial

Zacks Investment Research - 3 months ago

Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.

GlobeNewsWire - 3 months ago

Novel adoptive T cell therapy targets checkpoint-refractory solid tumors with neoantigen-specific T cells from peripheral blood Novel adoptive T cell therapy targets checkpoint-refractory soli...

GlobeNewsWire - 4 months ago

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today annou...

Seeking Alpha - 5 months ago

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT Filed IND application for GEN-011 and is working with the FDA to provide additional information Private Placement with Le...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced tha...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announc...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host it...

GlobeNewsWire - 6 months ago

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy

GlobeNewsWire - 7 months ago

Preliminary clinical data expected mid-2021 Preliminary clinical data expected mid-2021

GlobeNewsWire - 7 months ago

Data show immune responses occur rapidly after only two vaccinations and  can be sustained for more than one year

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announc...

GlobeNewsWire - 8 months ago

GEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021 GEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021

GlobeNewsWire - 8 months ago

Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT

Seeking Alpha - 8 months ago

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, AVGR, GOSS, VFF
Seeking Alpha - 8 months ago

Genocea Biosciences: Don't Sleep On This Small Biotech

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).

Seeking Alpha - 11 months ago

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination

Seeking Alpha - 1 year ago

Genocea Biosciences Inc (GNCA) CEO Chip Clark on Q3 2019 Results Earnings Call - Transcript

GlobeNewsWire - 1 year ago

Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™ Continued advancement of GEN-011, expect to file an IND in first half of 2020 Entered into a common stock purcha...

GlobeNewsWire - 1 year ago

Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced th...

Seeking Alpha - 1 year ago

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Genocea recently reported strong immunogenicity data from its phase 1/2a study using its neoantigen vaccine GEN-009 to treat patients with multiple types of cancer.

Seeking Alpha - 1 year ago

Genocea Biosciences recently delivered robust data for the Phase 1/2 trial studying GEN-009 at the 2019 Annual Meeting of the American Society of Clinical Oncology.

Seeking Alpha - 1 year ago

ATLAS was used to select HSV2 antigens incorporated into a therapeutic vaccine that reduced symptoms but not enough to advance into phase 3 studies.

Seeking Alpha - 1 year ago

Shares have gained around 40% since my initial article.

Benzinga - 1 year ago

Genocea Biosciences (NASDAQ: GNCA) shares rallied higher after the company presented results from lead neoantigen vaccine at the annual meeting of the American Society of Clinical Oncology 2019.

24/7 Wall Street - 1 year ago

Genocea Biosciences Inc. (NASDAQ: GNCA) is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO).

Market Watch - 1 year ago

Shares of Genocea Biosciences Inc. GNCA, +24.67% surged 101% in premarket trade Monday after the biotech announced promising data from an early-stage clinical trial of its lead drug candidate,...

Benzinga - 1 year ago

Genocea Biosciences announced Friday that the Journal of Clinical Oncology has selected the company’s GEN-009 clinical results presentation at the 2019 ASCO Annual Meeting as a top 10 featured...

Seeking Alpha - 1 year ago

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Genocea Biosciences.

About GNCA

Genocea Biosciences, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, In... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2014
CEO
William Clark
Employees
59
Stock Exchange
NASDAQ
Ticker Symbol
GNCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GNCA stock is "Strong Buy." The 12-month stock price forecast is 6.60, which is an increase of 103.70% from the latest price.

Price Target
$6.60
(103.70% upside)
Analyst Consensus: Strong Buy